nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

12.10.2021 | short review

Pancytopenia—a diagnostic challenge?

verfasst von: Klaus Geissler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Summary

Pancytopenia is a condition in which there is a lower-than-normal number of red and white blood cells and platelets in the blood. The spectrum of causes for the decrease of one or more blood cell lineages is broad including increased destruction, pooling by spleen, loss of blood cells, decreased production due to toxic and/or immune-mediated mechanisms and abnormalities due to clonal/malignant hematopoiesis. In this article common and/or typical causes of pancytopenia are presented with special emphasis on more or less disease specific features that may be useful clues in the differential diagnosis of this blood picture abnormality.

Vorheriger Artikel Practical considerations for the management of immune thrombocytopenic purpura

Nächster Artikel Laboratory thrombophilia screening: essentials for hematologists

Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. Am J Clin Pathol. 2013;139:9–29.CrossRef

Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 2017.

Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–62. https://doi.org/10.1056/NEJM199909303411407.CrossRefPubMed

Friedman RB, Anderson RE, Entine SM, Hirshberg SB. Effects of diseases on clinical laboratory tests. Clin Chem. 1980;26(4 Suppl):1D–476D.CrossRef

Warrell RP Jr, de Thé H, Wang ZY, et al. Acute promyelocytic leukemia. N Engl J Med. 1993;329(3):177–89. https://doi.org/10.1056/NEJM199307153290307.CrossRefPubMed

Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21. https://doi.org/10.1056/NEJMoa1300874.CrossRefPubMed

Young NS. Aplastic Anemia. N Engl J Med. 2018;379(17):1643–56. https://doi.org/10.1056/NEJMra1413485.CrossRefPubMedPubMedCentral

Spivak JL. Fundamentals of clinical hematology. 2nd ed. New York: Harper & Row; 1984.

Ohler L, Geissler K, Hinterberger W. Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. Wien Klin Wochenschr. 2003;115(13–14):537–46. https://doi.org/10.1007/bf03041036.CrossRefPubMed

10.

Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–99.CrossRef

11.

Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–74. https://doi.org/10.1056/NEJMra1904794.CrossRefPubMed

12.

List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65. https://doi.org/10.1056/NEJMoa061292.CrossRefPubMed

13.

Cervantes F, Barosi G. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. Semin Oncol. 2005;32(4):395–402. https://doi.org/10.1053/j.seminoncol.2005.04.011.CrossRefPubMed

14.

Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG‑A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703–11. https://doi.org/10.1016/0092-8674.CrossRefPubMed

15.

Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8. https://doi.org/10.1056/NEJM199511093331904.CrossRefPubMed

16.

Toh B‑H, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997;337(20):1441–8. https://doi.org/10.1056/NEJM199711133372007.CrossRefPubMed

17.

De Aizpurua HJ, Cosgrove LJ, Ungar B, Toh B‑H. Autoantibodies cytotoxic to gastric parietal cells in serum of patients with pernicious anemia. N Engl J Med. 1983;309(11):625–9. https://doi.org/10.1056/NEJM198309153091102.CrossRefPubMed

18.

Bethel KJ, Sharpe RW. Pathology of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16(1):15–31. https://doi.org/10.1016/s1521-6926(02)00087-7.CrossRefPubMed

19.

Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15. https://doi.org/10.1056/NEJMoa1014209.CrossRefPubMedPubMedCentral

20.

Koskela HLM, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–13. https://doi.org/10.1056/NEJMoa1114885.CrossRefPubMedPubMedCentral

21.

Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood. 2000;95(10):3219–22.CrossRef

22.

Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Front Immunol. 2016;16(7):364. https://doi.org/10.3389/fimmu.2016.00364.CrossRef

Titel: Pancytopenia—a diagnostic challenge?
verfasst von: Klaus Geissler
Publikationsdatum: 12.10.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00757-7

Practical considerations for the management of immune thrombocytopenic purpura

review

Practical issues in hematology

editorial

Ovarian cancer—ASCO annual meeting update 2021

ASCO 2021
short review

ASCO 2021—selection of personal highlights in early stage non-small cell lung cancer

Open Access
ASCO 2021
review

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

review

Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report

Open Access
case report

Springer Medizin Österreich

Pancytopenia—a diagnostic challenge?

Summary

Weitere Artikel der Ausgabe 4/2021

Practical considerations for the management of immune thrombocytopenic purpura

Practical issues in hematology

Ovarian cancer—ASCO annual meeting update 2021

ASCO 2021—selection of personal highlights in early stage non-small cell lung cancer

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Practical considerations for the management of immune thrombocytopenic purpura

Practical issues in hematology

Ovarian cancer—ASCO annual meeting update 2021

ASCO 2021—selection of personal highlights in early stage non-small cell lung cancer

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report